Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

2017 IPOs In Review: US Biopharma Offerings Rise, Values Decline At Mid-Year

Executive Summary

Nineteen biopharma firms went public in the US during the first half of 2017, but as the number of IPOs increased, the average return on first-time offerings decreased, raising a key question: can this pace of first-time offerings continue in the second half?

You may also be interested in...



Commercial Capsules: Soriot, IPOs, Deals And Hemophilia Data

IPOs are up, hemophilia is driving company pipelines, speculation over Pascal Soriot's career plans drive billions from AstraZeneca's market capitalization, Sanofi signs a $650m vaccine deal, private equity bidders up their offer for Stada and earnings season kicks off. Commercial capsule rounds up recent business news and trends reported by sister publication Scrip.

Finance Watch: Two More US Biopharma IPOs And Two New European VC Funds

Two biopharma IPOs in the US continue streak of (mostly) positive returns; two new European VC funds launch as Irish antibiotic developer raises $65m; and Halozyme, Ziopharm price offerings.

Biopharma IPOs Gain Momentum As Three More Launch In The US

UroGen, Biohaven and Ovid bring the year's US biopharma IPO count to 11 as returns remain in mostly positive territory. Ovid is one of only two newly public drug developers trading below its offering price.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel